119 related articles for article (PubMed ID: 3712213)
41. Comparison and evaluation of pharmacokinetics of PFOA and PFOS in the adult rat using a physiologically based pharmacokinetic model.
Loccisano AE; Campbell JL; Butenhoff JL; Andersen ME; Clewell HJ
Reprod Toxicol; 2012 Jul; 33(4):452-467. PubMed ID: 21565266
[TBL] [Abstract][Full Text] [Related]
42. Salivary antipyrine kinetics in hepatic and renal disease and in patients on anticonvulsant therapy.
Harman AW; Penhall RK; Priestly BG; Frewin DB; Phillips PJ; Clarkson AR
Aust N Z J Med; 1977 Aug; 7(4):385-90. PubMed ID: 270989
[TBL] [Abstract][Full Text] [Related]
43. Unaltered metabolism of phenytoin in thyroid disorders.
Mølholm Hansen J; Skovsted L; Kampmann JP; Lumholtz BI; Siersbaek-Nielsen K
Acta Pharmacol Toxicol (Copenh); 1978 May; 42(5):343-6. PubMed ID: 581029
[TBL] [Abstract][Full Text] [Related]
44. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes.
Ito K; Houston JB
Pharm Res; 2004 May; 21(5):785-92. PubMed ID: 15180335
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetic analysis of intravenously and orally administered quinidine in cows.
McGuirk SM; Muir WW; Sams RA
Am J Vet Res; 1981 Sep; 42(9):1482-7. PubMed ID: 7325456
[TBL] [Abstract][Full Text] [Related]
46. Comparative bioavaiability of four commercial quinidine sulfate tablets.
Strum JD; Colaizzi JL; Jaffe JM; Martineau PC; Poust RI
J Pharm Sci; 1977 Apr; 66(4):539-42. PubMed ID: 576879
[TBL] [Abstract][Full Text] [Related]
47. Interaction between phenytoin, 5-(p-hydroxyphenyl)-5-phenylhydantoin and valproate in the rat.
O'Leary TD; Sansom LN
J Pharmacol Exp Ther; 1981 Mar; 216(3):613-6. PubMed ID: 6782238
[TBL] [Abstract][Full Text] [Related]
48. Saliva and plasma clearance of antipyrine as reflectors of liver function.
Luoma PV; Sotaniemi EA
Eur J Drug Metab Pharmacokinet; 1981; 6(4):261-4. PubMed ID: 7333326
[TBL] [Abstract][Full Text] [Related]
49. Empirical and theoretical approaches for the prediction of human hepatic clearance using chimeric mice with humanised liver: the use of physiologically based scaling, a novel solution for potential overprediction due to coexisting mouse metabolism.
Matsumoto S; Kamimura H; Nishiwaki M; Cho N; Kato K; Yamamoto T
Xenobiotica; 2021 Sep; 51(9):983-994. PubMed ID: 34227923
[TBL] [Abstract][Full Text] [Related]
50. Quinidine-digoxin interaction: time course and pharmacokinetics.
Leahey EB; Bigger JT; Butler VP; Reiffel JA; O'Connell GC; Scaffidi LE; Rottman JN
Am J Cardiol; 1981 Dec; 48(6):1141-6. PubMed ID: 7304462
[TBL] [Abstract][Full Text] [Related]
51. Antipyrine, theophylline, and hexobarbital as in vivo P450 probe drugs.
Groen K; Breimer DD
Methods Enzymol; 1996; 272():169-77. PubMed ID: 8791775
[No Abstract] [Full Text] [Related]
52. Effects of cimetidine on quinidine distribution in rats.
Shibasaki S; Komoriya K; Gon S; Matsuura Y; Nishigaki R; Umemura K
J Pharmacobiodyn; 1987 Dec; 10(12):719-26. PubMed ID: 3451957
[TBL] [Abstract][Full Text] [Related]
53. Commentary: a physiological approach to hepatic drug clearance.
Wilkinson GR; Shand DG
Clin Pharmacol Ther; 1975 Oct; 18(4):377-90. PubMed ID: 1164821
[TBL] [Abstract][Full Text] [Related]
54. Changes in steady state digoxin pharmacokinetics during quinidine therapy in cardiac patients: influence of plasma quinidine concentration.
Pedersen KE; Christiansen BD; Klitgaard NA; Nielsen-Kudsk F
Acta Pharmacol Toxicol (Copenh); 1983 May; 52(5):357-63. PubMed ID: 6880771
[TBL] [Abstract][Full Text] [Related]
55. Modeled Rat Hepatic and Plasma Concentrations of Chemicals after Virtual Administrations Using Two Sets of in Silico Liver-to-Plasma Partition Coefficients.
Adachi K; Utsumi M; Sato T; Nakano H; Shimizu M; Yamazaki H
Biol Pharm Bull; 2023 Sep; 46(9):1316-1323. PubMed ID: 37380443
[TBL] [Abstract][Full Text] [Related]
56. Kinetic analysis of phenytoin disposition in rats with experimental renal and hepatic diseases.
Itoh T; Sawada Y; Lin TH; Iga T; Hanano M
J Pharmacobiodyn; 1988 May; 11(5):289-308. PubMed ID: 3171873
[TBL] [Abstract][Full Text] [Related]
57. Interaction of quinidine with anticonvulsant drugs.
Data JL; Wilkinson GR; Nies AS
N Engl J Med; 1976 Mar; 294(13):699-702. PubMed ID: 1250281
[TBL] [Abstract][Full Text] [Related]
58. Kinetics and dynamics of quinidine-N-oxide in healthy subjects.
Ha HR; Vozeh S; Uematsu T; Guentert TW; Follath F
Clin Pharmacol Ther; 1987 Sep; 42(3):341-5. PubMed ID: 3621790
[TBL] [Abstract][Full Text] [Related]
59. Distribution of quinidine in rats with carbon tetrachloride-intoxicated hepatic disease.
Sugihara N; Furuno K; Kita N; Murakami T; Yata N
J Pharmacobiodyn; 1992 Apr; 15(4):167-74. PubMed ID: 1494979
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetics of pentobarbital, quinidine, lidocaine, and theophylline in the thermally injured rat.
Fruncillo RJ; DiGregorio GJ
J Pharm Sci; 1984 Aug; 73(8):1117-21. PubMed ID: 6491915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
